Sign Up
OverviewAPI
Bristol Myers Squibb (BMY) reported Q3 results with revenues meeting estimates, but underperformed the S&P 500. Despite the decline in stock value, BMY is considered undervalued at $50, trading at a lower multiple than its 2023 expected earnings.

Ask a question